Tremfya Cost in 2026: Prices & How to Save
Tremfya Cost in 2026: Prices & How to Save
Open the pharmacy invoice for a single Tremfya injection and the number can stop you cold: roughly $14,566 for one dose at list price, and closer to $18,000 in cash at some pharmacies. For a medication you may take for years, that math gets frightening fast.
If you've been prescribed Tremfya for psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis, the price tag is real — but it isn't the whole story. What you actually pay depends on the form, your coverage, and which savings routes you're willing to explore.
At a glance
- The list price of Tremfya (generic name: guselkumab) is about $14,566 per single subcutaneous injection as of 2026.
- At U.S. pharmacies, the cash retail price for a 100 mg One-Press injector often runs $18,000–$19,000 per dose.
- On the standard psoriasis schedule (one injection every 8 weeks), Tremfya costs roughly $90,000–$100,000 per year at list price.
- No generic or biosimilar version is available in the U.S., and none is expected until around 2031.
- Cash-pay pricing through a licensed pharmacy network and switching to a lower-cost biologic are two of the few levers that meaningfully move the number.
How much does Tremfya cost in 2026?
Tremfya's manufacturer, Johnson & Johnson, lists the price at $14,566.44 per single subcutaneous injection or IV infusion. That's the wholesale anchor. Your pharmacy's cash price usually sits higher, because specialty pharmacies mark up above the list figure.
Here's what the cash retail price looks like by form, based on recent U.S. pharmacy data:
| Tremfya form and dose | Typical cash retail price |
|---|---|
| One-Press injector, 100 mg/mL | ~$18,960 |
| Prefilled syringe, 100 mg/mL | ~$18,890 |
| Prefilled pen, 200 mg/2 mL | ~$18,650 |
| IV solution, 200 mg/20 mL (infusion) | ~$14,950 |
Prices vary by pharmacy and location. Some discount-coupon programs bring a 100 mg injector down to roughly $14,700, which is closer to the list price but still five figures per shot.
One outlier worth understanding: you'll occasionally see a Tremfya price around $45. That's not a cash price — it's what some patients pay with insurance after their plan covers most of the cost. Without insurance, nobody is buying Tremfya for $45.
Tremfya cost per month and per year
Because Tremfya isn't a daily pill, the per-dose price only tells you so much. What matters for your budget is how often you inject and how those doses add up over a year.
For plaque psoriasis and psoriatic arthritis, the standard schedule is 100 mg at week 0, another 100 mg at week 4, then 100 mg every 8 weeks after that. In a typical maintenance year, that's about six to seven injections.
| Indication | Maintenance schedule | Approx. injections per year | Approx. annual cost at list price |
|---|---|---|---|
| Plaque psoriasis | 100 mg every 8 weeks | 6–7 | $90,000–$100,000 |
| Psoriatic arthritis | 100 mg every 8 weeks | 6–7 | $90,000–$100,000 |
| Crohn's disease / ulcerative colitis | IV induction, then 100 mg every 8 weeks or 200 mg every 4 weeks | 6–13 | $95,000–$190,000+ |
The inflammatory bowel disease numbers run higher for two reasons. Treatment usually starts with an intravenous induction phase — the induction pack alone can exceed $29,000 — and maintenance may be dosed as often as every four weeks, which roughly doubles the number of doses compared with the psoriasis schedule.
Spread across 12 months, even the lower end works out to something like $7,500–$8,500 a month. That's the reality behind the "how much does Tremfya cost per month" question, and it's why coverage and savings strategy matter so much.
Why is Tremfya so expensive?
Tremfya is a biologic — a medication grown in living cells rather than mixed in a chemical lab. Guselkumab is a monoclonal antibody that blocks interleukin-23 (IL-23), a signaling protein that drives the inflammation behind psoriasis and related conditions. Making a molecule like that is slow, technically demanding, and expensive to manufacture and store.
Then there's competition, or the lack of it. Small-molecule drugs get cheap generics once patents lapse. Biologics get biosimilars — highly similar, not identical, copies. A biosimilar can't legally launch until the original's patents expire and its exclusivity period ends.
For Tremfya, that wait is long. No biosimilar guselkumab is approved in the U.S., and based on the current patent picture, the earliest one is unlikely to arrive before roughly 2031. Until then, Johnson & Johnson has no direct competitor for this exact molecule, and the price reflects it. Tremfya generated about $3.67 billion in sales in 2024 — a drug priced to match its market position.
Savings tip: "No biosimilar yet" doesn't mean "no lower-cost option ever." Some conditions Tremfya treats can also be managed with older biologics that do have biosimilars — Humira (adalimumab) now has several. Whether one fits your case is a conversation for your prescriber, but it's a conversation worth having.
Tremfya cost with insurance and Medicare
Most commercial and Medicare plans do cover Tremfya, but coverage almost always comes with strings. Insurers commonly require prior authorization — your doctor has to document that Tremfya is medically necessary — and many plans also impose step therapy, meaning you may need to try and fail on a cheaper medication first.
Recent coverage data shows Tremfya is on the formulary for roughly 90% of Affordable Care Act plans and nearly all commercial plans, with somewhat lower coverage under Medicare Advantage and Part D. When it's covered, what you pay comes down to your plan's specialty-drug tier, your deductible, and your coinsurance. Some well-covered patients pay a modest copay per dose; others on high-deductible plans can face thousands out of pocket early in the year before coverage kicks in.
If you have Medicare, the 2025 out-of-pocket cap on Part D prescription spending changed the picture for high-cost drugs like this one. Once you hit the annual cap, your Part D plan covers the rest for the year. Your exact cost still depends on your specific plan, so confirm the details with your plan administrator before your first fill.
How to save on Tremfya
When a drug costs this much, "shop around" isn't a throwaway line — it's the strategy. A few routes are worth pricing out:
Compare cash-pay pricing through a licensed pharmacy network. Cash-pay services like CanAmerica Plus connect patients with licensed pharmacies, and the cash price for a specialty biologic can differ meaningfully from what a U.S. retail pharmacy quotes. Check the price on Tremfya and guselkumab directly and compare it against your local cash quote before you commit. Always confirm you're dealing with a licensed, verified pharmacy.
Ask about a lower-cost biologic. This is the highest-leverage move for many people. Skyrizi (risankizumab) works on the same IL-23 pathway, while Cosentyx (secukinumab), Stelara (ustekinumab), and Humira all treat overlapping conditions. Humira and Stelara now have biosimilars, which can lower the cost considerably. Never switch on your own — but do ask your doctor whether an alternative would work as well for you.
Use tax-advantaged dollars. A health savings account (HSA), flexible spending account (FSA), or health reimbursement arrangement (HRA) lets you pay with pre-tax money, which effectively discounts the cost by your tax rate.
Fill a larger supply and use mail order. If your plan and pharmacy allow it, a 90-day fill or a specialty mail-order pharmacy can reduce trips and sometimes lower the per-dose cost. Ask your specialty pharmacy what's available.
For a fuller picture of how these tactics play out across expensive autoimmune drugs, our guides to Humira cost and Skyrizi cost walk through the same math for closely related medications.
How Tremfya compares to other biologics on cost
Tremfya isn't uniquely expensive — it sits in a class where nearly every option carries a five-figure annual price. But the differences matter, especially where biosimilars exist.
| Medication (generic) | Class | Biosimilar available in U.S.? | Approx. list price per dose |
|---|---|---|---|
| Tremfya (guselkumab) | IL-23 inhibitor | No | ~$14,566 |
| Skyrizi (risankizumab) | IL-23 inhibitor | No | ~$18,000+ |
| Cosentyx (secukinumab) | IL-17 inhibitor | No | ~$7,600 |
| Stelara (ustekinumab) | IL-12/23 inhibitor | Yes (2025) | ~$25,000 (biosimilars lower) |
| Humira (adalimumab) | TNF inhibitor | Yes (multiple) | ~$6,900 (biosimilars lower) |
Dosing frequency changes the real-world comparison — a drug with a higher per-dose price but fewer doses per year can end up cheaper annually. Otezla (apremilast), an oral pill rather than an injection, and Rinvoq are also part of the psoriasis and psoriatic arthritis conversation, each with its own price and trade-offs. The point isn't that one is best; it's that "which biologic" is partly a cost question, and your prescriber can help you weigh it.
The bottom line
Tremfya runs about $14,566 per dose at list price and closer to $18,000 in cash at many U.S. pharmacies, which adds up to roughly $90,000 or more per year on the standard psoriasis schedule. With no biosimilar expected until around 2031, the price isn't dropping on its own anytime soon.
Your best moves: confirm your insurance coverage and any prior-authorization requirements, compare cash-pay pricing through a licensed pharmacy on both Tremfya and guselkumab, and ask your doctor whether a lower-cost biologic — including one with a biosimilar — would work for your condition. Small differences per dose become large differences per year.
Frequently asked questions
How much does one shot of Tremfya cost?
At list price, a single Tremfya injection is about $14,566. At U.S. pharmacies, the cash price for a 100 mg One-Press injector or prefilled syringe often runs $18,000–$19,000. Discount programs can bring it closer to $14,700, but it remains a five-figure expense per dose.
Why is Tremfya so expensive?
It's a biologic, which is costly to manufacture, and it has no direct competitor. Small-molecule drugs get cheap generics; biologics get biosimilars, and no biosimilar for guselkumab exists in the U.S. yet. Without competition, there's little pressure on the price.
Is there a generic or biosimilar for Tremfya?
Not in the U.S. Tremfya is available only as the brand-name biologic. Based on the current patent timeline, a biosimilar guselkumab isn't expected before roughly 2031.
How do people afford Tremfya?
Most people rely on insurance, which — after prior authorization — often covers the bulk of the cost. Beyond coverage, patients compare cash-pay pricing through licensed pharmacies, use HSA or FSA dollars, ask about lower-cost biologics (including Humira and Stelara biosimilars), and consider 90-day or mail-order fills to trim the per-dose price.
Is Tremfya or Skyrizi cheaper?
Both are IL-23 inhibitors with five-figure per-dose prices, and neither has a U.S. biosimilar. Tremfya's list price (~$14,566 per dose) is generally lower per dose than Skyrizi's, but the two use different dosing schedules, so the annual difference depends on your specific regimen. Compare both on a cash-pay basis and talk with your prescriber about which fits your condition.
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment. Pricing information is current as of the publication date but may change. Verify pricing directly before making purchasing decisions.
